ImCare Biotech

ImCare Biotech is a US-based, private biotech company founded in 2011, targeting liver cancer and related diseases through a dual approach of diagnostics and small molecule therapeutics. The company is in the pre-clinical/development stage, leveraging a management team with strong scientific and commercial expertise from institutions like Drexel University, McKinsey, and Cisco. Its core focus is on translating proprietary research into commercial diagnostic assays and drugs, with a clear vision to become a global leader in liver disease management.

Proprietary molecular biology and tissue culture platform for biomarker discovery and drug development, integrated with AI/software for diagnostic model building. Foundation includes patented technologies from founder Dr. Xuanyong Lu.

ImCare competes in the crowded liver cancer diagnostic space against established players like Roche, Abbott, and Fujirebio, as well as numerous startups. In therapeutics, it would face competition from major pharmaceutical companies with approved and pipeline drugs. Its differentiation relies on its proprietary multi-analyte biomarker approach and integrated AI capabilities.